FRC
FRC Logo
CommunityMarkets
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years
Rate us on TrustpilotLeave a review

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us
  • Leave a Review

Resources

  • Videos
  • Research Reports
  • Community
  • FAQ
  • How to use the site

Browse

  • Stock Directory
  • Stock Screener
  • Market Intel Weekly
  • Report Archive

Trackers

  • Congress Trading
  • Senate Trading
  • Congress Net Worth
  • Markets

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Strategies
Intel
Analysis
Community
Company ProfileGrifols, S.A.
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
GRFS
Grifols, S.A. Stock AnalysisComprehensive stock analysis for Grifols, S.A. (GRFS) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisGRFS
GRFS
Grifols, S.A.
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
GRFS
  1. Home
  2. Stocks
  3. Grifols, S.A.

Grifols, S.A.

🇺🇸GRFS•NASDAQ

Grifols, S.A.

🇺🇸GRFS•NASDAQ
Market cap
$7.17B
Sentiment

Your view on GRFS

Mkt Cap
$7.17B
Sentiment
Your view
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Grifols, S.A.

Industry
Drug Manufacturers - General
Sector
Healthcare
CEO
Jose Ignacio Abia Buenache
Headquarters
Avinguda de la Generalitat, 152, Barcelona, ES
Industry
Drug Manufacturers - General
Sector
Healthcare
CEO
Jose Ignacio Abia Buenache
Headquarters
Avinguda de la Generalitat, 152, Barcelona, ES
Description

Grifols, S.A. engages in the procurement, manufacture, preparation, and sale of therapeutic products, primarily hemoderivatives. The company operates through Bioscience, Hospital, Diagnostic, Bio Supplies, and Others divisions.

The Bioscience division researches, develops, produces, and markets plasma-derived medicines and other innovative solutions to treat patients with chronic, rare, prevalent, and life-threatening diseases. It offers immunoglobulins, alpha-1 antitrypsin, albumin, clotting factors, and hyperimmune globulins.

The Hospital division offers non-biological pharmaceutical products and medical supplies clinical nutrition, intravenous therapy, and medical devices.

The Diagnostic division researches, develops, produces, and commercializes diagnostic products that span the healthcare continuum–from prevention, screening, diagnosis, and prognosis to disease and treatment monitoring–to serve professionals.

The Bio Supplies division provides biological materials for life-science research, clinical trials, and for manufacturing pharmaceutical and diagnostic products. Its products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and other medical conditions.

The company serves public and private customers; and wholesalers, distributors, group purchasing organizations, blood banks, hospitals and care institutions, and national health systems. Grifols, S.A. has a technology collaboration agreement with Mondragon. The company was founded in 1940 and is headquartered in Barcelona, Spain.

Financial Data

Stock Data

Price chart, volume, and trading data.

FRC Fair Value Algorithm

What the FRC Fair Value algorithm says it is worth vs. the current price — FRC's own, on every stock.

About this section

Fair value for Grifols, S.A. from FRC's valuation model, read against the market price. GRFS last traded at $8.47, 15.8× trailing earnings — the estimate is read against that market price. The model runs on every stock on the platform and shows the estimate per share and the date it was calculated. A free account covers 3 company valuations a month; a paid subscription is unlimited.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

About this section

Valuation, profitability, liquidity and leverage ratios for Grifols, S.A.. Starting points for Grifols, S.A.: P/E 15.8, EPS $0.72, beta 1.19 — an Drug Manufacturers - General name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

About this section

Dividend history, yield and payout sustainability for Grifols, S.A.. Grifols, S.A. paid $0.11 per share over the last year — a 1.2% yield at the current $8.47 price. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

About this section

Reported vs. expected earnings history for Grifols, S.A.. Trailing twelve-month EPS for Grifols, S.A. stands at $0.72. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Wall Street Analyst Estimates

Analysts' price targets, ratings, and revenue and EPS estimates.

Third partyAs of Nov 18, 2026 · EUR

Price targets, ratings and estimates published by outside analysts. Not FRC research, not a recommendation, and not the FRC Fair Value: that is FRC's proprietary model, built on the cash a company generates.

Analyst Ratings

Buy8 ratings
  • Strong Buy0
  • Buy4
  • Hold2
  • Sell2
  • Strong Sell0

Earnings Estimate

EPSCurrent QtrDec 2026Next QtrMar 2027Current YearFY Dec 2026Next YearFY Dec 2027
Avg. estimateEUR 0.30EUR 0.27EUR 0.87EUR 1.07
Low estimateEUR 0.26EUR 0.27EUR 0.80EUR 1.00
High estimateEUR 0.33EUR 0.27EUR 0.95EUR 1.14
No. of analysts1112
Year-ago EPSEUR 0.29EUR 0.17EUR 0.57—
Growth+2.6%+53.9%+53.3%—

Revenue Estimate

RevenueCurrent QtrDec 2026Next QtrMar 2027Current YearFY Dec 2026Next YearFY Dec 2027
Avg. estimateEUR 2.07BEUR 3.22BEUR 7.71BEUR 8.20B
Low estimateEUR 2.07BEUR 3.22BEUR 7.66BEUR 8.14B
High estimateEUR 2.07BEUR 3.22BEUR 7.77BEUR 8.27B
No. of analysts1145
Year-ago revenueEUR 1.96BEUR 1.73BEUR 7.23B—
Growth+5.5%+86.1%+6.7%—
Recent analyst actions15 rating and price-target changes, latest Oct 26, 2026 — with the analyst, firm and source

Source: Wall Street analysts' published price targets, ratings and estimates, compiled by Financial Modeling Prep; as of Nov 18, 2026. Not FRC research or a recommendation.

Financial Statements

Income statement, balance sheet, and cash flow statements.

About this section

Income statement, balance sheet and cash flow history for Grifols, S.A.. Grifols, S.A. has reported as a listed company since 2011. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Peer Comparison

Comparables

List of peer companies in the same industry.

Peers, the industry, and the funds that hold GRFS20 companies · 8 funds
Compare GRFS with its peers, side by sidePremiumRatios, margins, valuation and leverage of the peers below — one table, one glance.Open Comparable Analysis

Peer companies

Market cap

  • ABTAbbott LaboratoriesMedical - Devices$181.0B
  • ADMAADMA Biologics, Inc.Biotechnology$3.0B
  • BDXBecton, Dickinson and CompanyMedical - Instruments & Supplies$58.9B
  • BIOBio-Rad Laboratories, Inc.Medical - Devices$10.0B
  • HAEHaemonetics CorporationMedical - Devices$5.6B
  • MRVIMaravai LifeSciences Holdings, Inc.Biotechnology$2.1B
  • QDELQuidelOrtho CorporationMedical - Specialties$657M
  • TECHBio-Techne CorporationBiotechnology$11.4B

More Drug Manufacturers - General companies

  • PFE.NEPfizer Inc.NEO
  • PTKFFPT Kalbe Farma Tbk.OTC$3.2B
  • PTKFYPT Kalbe Farma Tbk.OTC$15M
  • RHHBFRoche Holding AGOTC$390.8B
  • RHHBYRoche Holding AGOTC$383.1B
  • RHHVFRoche Holding AGOTC$386.4B
  • SCLXScilex Holding CompanyNASDAQ$4M
  • SCLXWScilex Holding CompanyNASDAQ$14M
  • SNPHFSanten Pharmaceutical Co., Ltd.OTC$3.1B
  • SNPHYSanten Pharmaceutical Co., Ltd.OTC$3.7B
  • SNYSanofiNASDAQ$113.1B
  • SNYNFSanofiOTC$115.1B

ETFs holding Grifols, S.A.

% of the fund

  • IBBiShares Biotechnology ETF$11.1B in assets0.14%
  • BINVBrandes International ETF$572M in assets1.43%
  • KOMPState Street SPDR S&P Kensho New Economies Composite ETF$2.3B in assets0.13%
  • BSMCBrandes U.S. Small-Mid Cap Value ETF$179M in assets1.73%
  • SPDWState Street SPDR Portfolio Developed World ex-US ETF$41.0B in assets0.01%
  • CGICCapital Group International Core Equity ETF$2.6B in assets0.04%
  • APIEActivePassive International Equity ETF$1.1B in assets0.02%
  • QQQSInvesco NASDAQ Future Gen 200 ETF$20M in assets0.70%

Largest holders first, then the funds most concentrated in GRFS.

Open Comparable Analysis
Ownership & News

Institutional Ownership

Which funds and firms own the stock.

About this section

Which institutions hold Grifols, S.A., and how their positions are changing. At a $7.17B market value, institutional positions materially move Grifols, S.A.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.

House Trading

U.S. Representative disclosures filed under the STOCK Act.

About this section

U.S. House of Representatives disclosures naming Grifols, S.A.. Representatives' reported transactions in this security, shown next to the company's fundamentals.

News

Latest headlines and market coverage.

About this section

Latest headlines and company announcements for Grifols, S.A.. Coverage tracks Grifols, S.A. within Drug Manufacturers - General (Healthcare). Press releases and market coverage, newest first.

Discussion

Comments

Comments and replies from FRC members about this company.

No comments yet

Be the first to ask a question or say what you make of Grifols, S.A.

GRFS Analysis
Fair
Past1
Growth3
Health3
Profit3
Value2

News

Latest Market News